We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan to Buy Abbott’s International Generic Drug Assets for $5.3 Billion
Mylan to Buy Abbott’s International Generic Drug Assets for $5.3 Billion
Generic drugmaker Mylan agreed to pay Abbott Labs $5.3 billion in stock to acquire part of its international generic drug business in a deal that vastly spreads the geographic reach of the Pennsylvania-based firm.